Streetbeat News

Stock Prices

WGS

BTIG analyst Mark Massaro maintains a Buy rating on GeneDx Holdings (NASDAQ:WGS) and raises the price target from $11 to $15, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 5:34 pm

FuzzyPanda, a known short seller, has announced on X (formerly Twitter) that they continue to hold a short position in Globe Life Inc. ($GL), indicating ongoing bearish sentiment towards the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 5:32 pm

AAPL

AMD

INTC

NVDA

QCOM

TSM

TSMC reported strong Q1 results, surpassing estimates due to high AI demand. Its customers, including NVIDIA, Apple, AMD, and Qualcomm, contribute to its growth. NVIDIA aims to expand into AI software services, mirroring TSMC's role in chip manufacturing. TSMC's Q2 guidance reflects strong demand but anticipates a slight margin decline due to an earthquake and higher costs, though with minimal revenue impact. TSMC plans to mass-produce more efficient 2-nanometer chips by 2025 and expects significant revenue growth from AI processors.

Portfolio Pulse from Upwallstreet

April 22, 2024 | 5:31 pm

MLEC

MTTR

TSLA

VAXX

Vaxxinity, Inc. announced its intention to voluntarily delist and deregister its Class A common stock, causing a sharp decline in its shares by around 55%. Other stocks experienced significant movements, with Matterport, Inc. seeing a jump due to an acquisition announcement by CoStar Group, and various companies reporting gains due to positive developments such as USDA approvals, IPO pricing, and compliance regains. Conversely, several companies faced declines due to negative news such as wind-down activities, delisting determinations, and price reductions.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 5:26 pm

PHIO

Phio Pharmaceuticals' shares surged following the announcement that its intratumoral injection, PH-762, showed promising results in inhibiting tumor growth in murine tumor models and may also generate memory-specific T cells.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 5:25 pm

AAPL

VGT

XLK

Morgan Stanley analyst Erik Woodring maintained an Overweight rating on Apple Inc (AAPL) but lowered the price target from $220 to $210, citing a similar earnings setup to 3 months ago with expectations of a slight upside to March quarter revenue but a sizable June quarter guide-down vs. consensus. Despite a 12% lower share price and more harmful buy-side sentiment, Woodring sees potential for a relief rally post-earnings, especially with the upcoming WWDC and new AI software features. Apple's stock has lost 11% year-to-date, but there's nearly 30% upside to the new price target. Investors can also gain exposure to Apple through ETFs like Vanguard Information Tech ETF (VGT) and SPDR Select Sector Fund - Technology (XLK).

Portfolio Pulse from Anusuya Lahiri

April 22, 2024 | 5:24 pm

RACE

Morgan Stanley analyst Adam Jonas maintains an Overweight rating on Ferrari (NYSE:RACE) with a $400 price target, indicating a positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 5:21 pm

WOLF

A significant option activity was observed for Wolfspeed, with a sweep of 1309 calls at a strike price of $25.5, priced at $0.9 each, compared to an open interest of 51. This activity occurred when Wolfspeed's stock was trading at $24.22.

Portfolio Pulse from Charles Gross

April 22, 2024 | 5:21 pm

WOLF

Wolfspeed's stock price increased after Jana Partners recommended the company to explore a sale and review strategic alternatives.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 5:07 pm

DHR

Financial analysis reveals a bearish sentiment on Danaher (NYSE:DHR) with 66% of options trades showing bearish tendencies. The analysis highlighted 9 unusual trades, predominantly puts, indicating a focus on a price band between $195.0 and $250.0. Current market data shows DHR trading up by 0.18% at $235.93, with an anticipated earnings release in 1 day. Industry analysts have set an average target price of $270.0, with Barclays maintaining an Equal-Weight rating at $260 and HSBC upgrading to Buy with a target of $280.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 5:02 pm